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1. INTRODUCTION {#dom12848-sec-0001}
===============

Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have recently been developed as a novel class of glucose‐lowering agents for the management of type 2 diabetes (T2D).[1](#dom12848-bib-0001){ref-type="ref"}, [2](#dom12848-bib-0002){ref-type="ref"} SGLT2 inhibitors enhance urinary glucose excretion (UGE), thereby ameliorating both pre‐ and postprandial glucose excursions insulin‐independently, and also lead to substantial body weight reduction. Clinical trials have demonstrated the efficacy and safety of SGLT2 inhibitors, as a class, in people with T2D; however, there are concerns regarding severe adverse events associated with the use of SGLT2 inhibitors in real clinical settings.[3](#dom12848-bib-0003){ref-type="ref"} Among these, diabetic ketoacidosis (DKA) near normoglycaemia or even euglycaemic DKA in individuals receiving SGLT2 inhibitors has drawn considerable attention.[4](#dom12848-bib-0004){ref-type="ref"}, [5](#dom12848-bib-0005){ref-type="ref"}, [6](#dom12848-bib-0006){ref-type="ref"} SGLT2 inhibitors lower plasma glucose and circulating insulin levels through enhancement of UGE; they also enhance glucagon secretion. Reduced insulin and elevated glucagon levels stimulate lipolysis in fat and hepatic ketogenesis, which could trigger onset of euglycaemic DKA under certain conditions, such as insulin‐dependent type 1 diabetes (T1D) and T2D characterized primarily by β‐cell dysfunction.[4](#dom12848-bib-0004){ref-type="ref"}, [5](#dom12848-bib-0005){ref-type="ref"}, [6](#dom12848-bib-0006){ref-type="ref"} Recently, it was reported that a Japanese patient with T2D on a strict low‐carbohydrate diet developed euglycaemic DKA after initiation of the SGLT2 inhibitor ipraglifrozin.[7](#dom12848-bib-0007){ref-type="ref"} It is possible that low carbohydrate intake together with SGLT2 inhibitor usage could have limited circulating insulin levels and thereby induced euglycaemic DKA. The American Diabetes Association sets no general recommendations on the carbohydrate content of meals.[8](#dom12848-bib-0008){ref-type="ref"} The Japanese Diabetes Society recommends that individuals with diabetes should normally take 50% to 60% of total energy from carbohydrates (TEC),[9](#dom12848-bib-0009){ref-type="ref"} but indicates that \<50% TEC may be allowed, depending on patient preference and diabetes pathophysiology. However, there has been no examination of safety and efficacy of SGLT2 inhibitors with regard to different meal compositions, especially carbohydrate content and glycaemic index (GI).

In the present study, we compared the efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese people with T2D receiving meals of different carbohydrate content (55% vs 40% of TEC) and differing GIs.

2. METHODS {#dom12848-sec-0002}
==========

2.1. Study protocol {#dom12848-sec-0003}
-------------------

This was a multicentre, randomized, open‐label, 3‐arm parallel comparative study in Japanese people with T2D ([ClinicalTrials.gov](http://ClinicalTrials.gov), NCT02500186 and UMIN, UMIN000017838). Eligible participants were randomly assigned into 3 groups in a 1:1:1 ratio (Figures S1 and S2). Those participants who were taking 1 oral antidiabetic drug or a glucagon‐like peptide‐1 (GLP‐1) receptor agonist underwent a washout period of at least 4 weeks before randomization. Participants in each group consumed the test meals of 1800 kcal/d with different carbohydrate adjustment (the high carbohydrate \[HC\]‐high GI \[HGI\] group received 55% TEC and HGI meals; the HC‐low GI \[LGI\] group received 55% TEC and LGI meals; and the low carbohydrate \[LC\]‐HGI group received 40% TEC and HGI meals) for 14 days (days 1‐14) as described in Appendix S1. Participants received oral luseogliflozin 2.5 mg before breakfast once daily for the final 7 days (days 8‐14). Blood sampling was conducted on days 1, 8 and 15; continuous glucose monitoring (CGM) was performed twice during the trial (days 5‐8 and days 12‐15), as described in Appendix S1. This trial was conducted in 2 medical institutions in Osaka, Japan after obtaining approval from both ethics committees. Written informed consent was obtained from all participants.

2.2. Study population {#dom12848-sec-0004}
---------------------

Eligible participants were aged 20 to 64 years, had a treatment history of a single oral hypoglycaemic agent or GLP‐1 receptor agonist with glycated haemoglobin (HbA1c) concentration ≤10.0% (≤86 mmol/mol) or no drug treatment with HbA1c concentration 7.0% to 10.0% (53‐86 mmol/mol) and body mass index (BMI) ≥20 and \<30 kg/m^2^. Participants with T1D, renal impairment with estimated glomerular filtration rate \<45 mL/min/1.73 m^2^, liver disease, cardiac disease, serious gastrointestinal tract disease, history of gastrointestinal surgery, alcohol abuse, malignancy, or pregnancy were excluded. The sample size was determined with reference to a recent clinical trial of luseogliflozin.[10](#dom12848-bib-0010){ref-type="ref"}

2.3. Study assessments {#dom12848-sec-0005}
----------------------

The primary endpoints were mean, SD, area under the curve (AUC) of glucose levels, and mean amplitude of glycaemic excursions (MAGE) derived from CGM data.[11](#dom12848-bib-0011){ref-type="ref"} Other endpoints included fasting plasma glucose (FPG), insulin, C‐peptide, glucagon, ketone bodies and non‐esterified fatty acids. These endpoints were assessed in the full analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of efficacy data available). Adverse events, using system organ class/preferred terms, and adverse drug reactions were summarized for the safety analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of safety data available).

2.4. Statistical analysis {#dom12848-sec-0006}
-------------------------

All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Baseline characteristics were compared using analysis of variance; a significance level of 15% (2‐sided) was used to examine the heterogeneity of participant characteristics. Repeated measures were assessed using mixed‐design analysis of covariance. The unrestricted least significant difference method was applied to calculate the least squares mean and 95% confidence interval for changes in efficacy variables. Statistical significance was determined at the 5% level.

3. RESULTS {#dom12848-sec-0007}
==========

Twenty‐four Japanese people with T2D were recruited and randomly assigned into 3 groups: HC‐HGI, HC‐LGI and LC‐HGI (Figure S1). These groups had similar baseline data (Table [1](#dom12848-tbl-0001){ref-type="table-wrap"}), the duration of T2D in the LC‐HGI group being slightly longer than in the HC‐HGI and HC‐LGI groups, but the difference was non‐significant statistically.

###### 

Demographic data of participants in full analysis set

                                                           HC‐HGI group    HC‐LGI group    LC‐HGI group    *P*
  -------------------------------------------------------- --------------- --------------- --------------- -------
  Number of participants (men, women)                      8 (5, 3)        8 (6, 2)        7 (7, 0)        
  Age, years                                               54.3 ± 5.2      55.0 ± 5.0      56.9 ± 7.3      .6838
  Duration of type 2 diabetes, years                       4.4 ± 3.3       4.5 ± 3.5       7.6 ± 4.3       .1993
  BMI, kg/m^2^                                             24.31 ± 2.04    24.50 ± 2.74    26.03 ± 2.66    .3709
  Systolic blood pressure, mm Hg                           119.9 ± 14.0    123.3 ± 17.8    118.3 ± 9.9     .7939
  Diastolic blood pressure, mm Hg                          73.0 ± 12.4     76.4 ± 8.1      73.9 ± 5.0      .7506
  HbA1c, %                                                 7.56 ± 1.16     7.39 ± 0.85     7.57 ± 0.66     .9069
  FPG, mmol/L                                              7.95 ± 2.33     8.68 ± 2.37     8.63 ± 1.30     .7465
  Fasting insulin, pmol/L                                  55.6 ± 45.1     55.6 ± 22.9     57.6 ± 16.7     .9902
  Fasting glucagon, ng/L                                   185.9 ± 52.7    160.3 ± 30.2    161.6 ± 22.9    .3430
  SUIT                                                     27.49 ± 9.45    28.22 ± 15.33   26.53 ± 7.55    .9601
  HOMA‐IR                                                  3.2 ± 3.2       2.9 ± 1.0       3.2 ± 1.1       .9453
  HOMA‐β                                                   35.5 ± 20.2     38.8 ± 23.8     34.3 ± 12.3     .8982
  Total cholesterol, mmol/L                                5.8 ± 1.2       4.9 ± 0.6       5.5 ± 0.8       .2148
  HDL cholesterol, mmol/L                                  1.6 ± 0.5       1.8 ± 0.3       1.2 ± 0.2       .1702
  Triglycerides, mmol/L                                    1.3 ± 1.0       1.8 ± 0.7       1.7 ± 0.7       .4039
  Estimated glomerular filtration rate, mL/min/1.73 m^3^   86.31 ± 23.07   87.25 ± 13.91   82.05 ± 17.36   .8506

Values are mean ± SD or n (%). Each item was compared among the 3 groups using analysis of variance. A significance of P \< .15 (2‐sided) was taken to indicate heterogeneity among the study groups.

Abbreviations: HOMA‐β, homeostatic model assessment of β‐cell function; HOMA‐IR, homeostatic model assessment of insulin resistance; SUIT, secretory unit of islet in transplantation.

Postprandial CGM values in the HC‐HGI group were consistently higher than in the HC‐LGI and LC‐HGI groups before and after initiation of luseogliflozin treatment (Figure S3). The HC‐HGI group had higher peak blood glucose level (BG~max~), AUC over 48 hours (AUC~0‐48h~), and AUC~0‐48h~ for glucose levels \>10.0 mmol/L (high‐range AUC~0‐48h~); mean, SD and MAGE values were higher than in the HC‐LGI and LC‐HGI groups (Table [2](#dom12848-tbl-0002){ref-type="table-wrap"}), although the differences were not statistically significant. Importantly, luseogliflozin treatment significantly decreased the AUC and the mean of CGM data in all 3 groups. In the LC‐HGI group, lower peak blood glucose level (BG~min~) and area over the curve over 48 hour (AOC~0‐48h~) for glucose levels \<3.9 mmol/L (low‐range AOC~0‐48h~) post‐dose were significantly different from pre‐dose, possibly because of a single participant who had extremely low blood glucose levels at night. The participant was not excluded from the analysis set because the low level of glucose was possibly attributable to CGM sensor problems.

###### 

Parameters derived from continuous glucose monitoring values

                                      HC‐HGI   HC‐LGI                                           LC‐HGI                                                                                                                                
  ----------------------------------- -------- ------------------------------------------------ -------- -------- ----------------------------------------------- -------- -------- ------------------------------------------------- --------
  BG~max~, (mmol/L)                   13.17    12.13                                            −1.05    12.47    11.16                                           −1.31    11.35    10.29                                             −1.06
  BG~min~, (mmol/L)                   4.56     4.27                                             −0.29    4.59     4.09                                            −0.50    4.76     3.79[\*](#dom12848-note-0005a){ref-type="fn"}     −0.97
  AUC~0−48h~, (mmol·h/L)              380.52   340.06                                           −40.46   345.90   306.74                                          −39.16   347.08   296.69[\*](#dom12848-note-0005a){ref-type="fn"}   −50.39
  High−range AUC~0−48h~, (mmol·h/L)   20.30    10.57[\*](#dom12848-note-0005a){ref-type="fn"}   −9.73    8.79     2.88[\*](#dom12848-note-0005a){ref-type="fn"}   −5.91    3.89     0.56                                              −3.33
  Low−range AOC~0−48h~, (mmol·h/L)    0.19     0.53[\*](#dom12848-note-0005a){ref-type="fn"}    0.34     0.10     0.08                                            −0.02    0.00     1.50[\*](#dom12848-note-0005a){ref-type="fn"}     1.50
  Mean (mmol/L)                       7.94     7.09                                             −0.85    7.22     6.40                                            −0.82    7.24     6.19[\*](#dom12848-note-0005a){ref-type="fn"}     −1.05
  SD (mmol/L)                         2.20     1.96[\*](#dom12848-note-0005a){ref-type="fn"}    −0.24    1.77     1.70[\*](#dom12848-note-0005a){ref-type="fn"}   −0.08    1.54     1.53                                              −0.01
  MAGE, (mmol/L)                      5.28     5.10                                             −0.18    4.71     4.53                                            −0.18    4.18     3.87                                              −0.31
  MODD, (mmol/L)                      1.28     1.14                                             −0.14    1.21     1.22                                            0.01     0.91     1.00                                              0.09

Minimum mean−square values and the differences of minimum mean−square values of Days 6−7 (− Luseo) and Days 13−14 (+ Luseo) were calculated.

 Indicates *P* \< 0.05 versus − Luseo.

Abbreviations: BG~max~, peak blood glucose level; AUC0−48h, area under the curve over 48 h; high−range AUC~0−48h~, AUC~0−48h~ for glucose levels ≥ 181 mg/dL; (low−range AOC~0−48h~, area over the curve over 48 h for glucose levels \< 70 mg/dL; HC−HGI, high carbohydrate−high glycemic index; HC−LGI, high carbohydrate−low glycemic index; SD, standard deviation of the mean glucose concentration; LC−HGI, low carbohydrate−high glycemic index; MAGE, mean amplitude of glycemic excursions; MODD, mean of the daily difference.

The FPG values on days 1, 8 and 15 did not differ among the 3 groups (Figure S4), while FPG values on days 8 and 15 were lower than on day 1 in the HC‐LGI and LC‐HGI groups and, on day 15, were lower than on day 1 in the HC‐HGI group. Insulin and C‐peptide levels on days 1, 8 and 15 did not differ among the 3 groups, while insulin and C‐peptide levels on day 15 were significantly lower than on day 1 in all 3 groups. Insulin and C‐peptide levels on day 15 were reduced, possibly as a result of FPG reduction by combined action of test meals and luseogliflozin because secretory unit of islet in transplantation and homeostatic model assessment of β‐cell function (Figure S5) did not change between days 1 and 15. Glucagon on days 1, 8 and 15 did not differ among the 3 groups, while glucagon levels on day 8 and day 15 were lower than on day 1 in all 3 groups, with statistical significance only in the HC‐HGI and HC‐LGI groups. Unlike previous reports,[12](#dom12848-bib-0012){ref-type="ref"}, [13](#dom12848-bib-0013){ref-type="ref"} no glucagon elevation was observed in response to luseogliflozin administration.

Ketone bodies on days 1 and 8 did not differ among the 3 groups (day 1: HC‐HGI 139.1 ± 193.3 µmol/L; HC‐LGI 65.1 ± 41.1 µmol/L and LC‐HGI 115.3 ± 158.2 µmol/L; day 8: HC‐HGI 183.8 ± 155.4 µmol/L, HC‐LGI 196.5 ± 132.8 µmol/L and LC‐HGI 262.7 ± 138.1 µmol/L), while ketone bodies on day 15 were significantly higher in the LC‐HGI group compared with the HC‐HGI and HC‐LGI groups (day 15: HC‐HGI 502.9 ± 365.2 µmol/L, HC‐LGI 360.9 ± 184.7 µmol/L and LC‐HGI 752.4 ± 249.2 µmol/L \[Figure S4\]). Other variables are shown in Figures S4 to S7.

All adverse events were mild in severity (Table S1). Among them, somnolence and urinary frequency were judged as adverse drug reactions; dermatitis was attributable to contact with fixed tape for CGM.

4. DISCUSSION {#dom12848-sec-0008}
=============

In the present study, we found that luseogliflozin ameliorated hyperglycaemia in Japanese people with T2D receiving the 3 different test meals; however, ketone bodies were significantly increased by luseogliflozin in the LC‐HGI group.

Luseogliflozin improved AUC~0‐48h~ and mean of CGM data in all 3 groups, indicating that differences in carbohydrate content (55% vs 40% of TEC) and GI (white rice vs brown rice) did not affect the glucose‐lowering effects. Luseogliflozin did not affect SD or MAGE values, confirming that SGLT2 inhibitors improve glycaemia without affecting glucose variability.[14](#dom12848-bib-0014){ref-type="ref"}

Luseogliflozin significantly increased ketone bodies in the LC‐HGI group compared with the HC‐HGI and HC‐HGI groups, suggesting that reducing carbohydrate content substantially, together with SGLT2 inhibitor therapy, could trigger euglycaemic DKA. While the euglycaemic DKA cases reported in the USA were mostly in insulin‐dependent T1D,[4](#dom12848-bib-0004){ref-type="ref"}, [5](#dom12848-bib-0005){ref-type="ref"} a number of euglycaemic DKA cases have been reported in Japanese people with T2D receiving SGLT2 inhibitors.[6](#dom12848-bib-0006){ref-type="ref"} This difference might be attributable to the fact that T2D in East‐Asian populations, including Japanese populations, is characterized primarily by β‐cell dysfunction rather than insulin resistance and subsequent hyperinsulinaemia. Indeed, many euglycaemic DKA cases in Japanese people with T2D receiving SGLT2 inhibitors occurred after withdrawal of sulphonylureas and/or insulin.[6](#dom12848-bib-0006){ref-type="ref"} The present study showed that ketone bodies were significantly increased by luseogliflozin in the LC‐HGI group, suggesting that SGLT2 inhibitors might trigger onset of euglycaemic DKA in individuals on a strict LC diet, with or without withdrawal of insulin and/or sulphonylureas.

Limitations of the present study include the lack of UGE measurements because of difficulties in 24‐hour urine collection for outpatient participants; however, it is of interest to investigate the effects of carbohydrate intake adjustments on UGE before and after SGLT2 inhibitor treatment. UGE occurs when plasma glucose levels are higher than the renal threshold and SGLT2 inhibitor treatment lowers the threshold.[15](#dom12848-bib-0015){ref-type="ref"} Because glucose profiles of the HC‐LGI and LC‐HGI groups were similar and lower than in the HC‐HGI group before and after luseogliflozin treatment in the present study (Figure S3 and Table [2](#dom12848-tbl-0002){ref-type="table-wrap"}), the UGEs in the HC‐LGI and LC‐HGI groups might well be similar and lower than in the HC‐HGI group.

It is also uncertain whether 1 week is sufficient to stabilize the effects of dietary interventions in the absence or presence of luseogliflozin; it was previously shown that inter‐day variability of daily glucose profiles over 3 consecutive days was minimal (mean of daily difference \[MODD\] 1.3‐1.6 mmol/L) when food consumption was tightly controlled,[16](#dom12848-bib-0016){ref-type="ref"} as it was in the present study (MODD 0.9‐1.3 mmol/L); however, the effects during days 8 to 15 might partly be derived from the combined action of luseogliflozin and the dietary interventions.

In addition, the present study compared the effects of SGLT2 inhibitor use and carbohydrate intake adjustments for a short duration with a relatively small sample size; further investigations are necessary to address long‐term safety and efficacy of SGLT2 inhibitors in individuals receiving meals of various carbohydrate content.

In conclusion, the present study shows the glucose‐lowering effects of luseogliflozin, typical of SGLT2 inhibitors, with limited adverse events in Japanese people with T2D receiving meals consisting of 40% to 55% TEC with either an HGI or a LGI; however, our results suggest that the carbohydrate content of meals can play an important role in SGLT2 inhibitor‐associated hepatic ketogenesis and onset of euglycaemic DKA.
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